Asthma. Mixed Asthma
Conditions
Interventions
Intervention 1: Intervention group: Tablets of ?Atorvastatin are product of IRAN and 40 mg. Therapy is with one tablet daily for eight weeks. Intervention 2: Control group: Placebo will be given 1 ti
Treatment - Drugs
Placebo
Intervention group: Tablets of ?Atorvastatin are product of IRAN and 40 mg. Therapy is with one tablet daily for eight weeks.
Control group: Placebo will be given 1 times daily for 8 weeks.
Sponsors
Vice chancellor for research, 7th floor, Central building of SUMS, Zand Ave
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Asthma patients with a history of more than one year, aged 18 till 60 years are enrolled. Exclusion criteria: Lower respiratory infection 4 weeks before entering the study; more than 10 pack-year of smoking or smoking in the last 3 months; pregnancy or breastfeeding; current use of statins or previous side effects of statin or drugs that interact with statins such as antifungal, antibiotic macrolide, cyclosporine, germifibrosil, verapamil and amiodarone; hepatitis or active liver disease; myopathy or myositis.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum level of periostin. Timepoint: Befor intervention and eight weeks after intervention. Method of measurement: ng/mL.;Serum level of IL-13. Timepoint: Befor intervention and eight weeks after intervention. Method of measurement: pg/mL. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug/placebo reaction. Timepoint: 4 and 8 weeks after intervention. Method of measurement: Ask from the patient and laboratory data.;Forced expiratory volume in first second. Timepoint: Before intervention and 4 and 8 weeks later. Method of measurement: liters per minute. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSamrad Mehrabi
Shiraz University of Medical Sciences
Outcome results
None listed